ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

TY - JOUR

T1 - ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis

T2 - Fusarium spp., Scedosporium spp. and others

AU - Tortorano, A M

AU - Richardson, M

AU - Roilides, E

AU - van Diepeningen, A

AU - Caira, M

AU - Munoz, P

AU - Johnson, E

AU - Meletiadis, J

AU - Pana, Z-D

AU - Lackner, M

AU - Verweij, P

AU - Freiberger, T

AU - Cornely, O A

AU - Arikan-Akdagli, S

AU - Dannaoui, E

AU - Groll, A H

AU - Lagrou, K

AU - Chakrabarti, A

AU - Lanternier, F

AU - Pagano, L

AU - Skiada, A

AU - Akova, M

AU - Arendrup, M C

AU - Boekhout, T

AU - Chowdhary, A

AU - Cuenca-Estrella, M

AU - Guinea, J

AU - Guarro, J

AU - de Hoog, S

AU - Hope, W

AU - Kathuria, S

AU - Lortholary, O

AU - Meis, J F

AU - Ullmann, A J

AU - Petrikkos, G

AU - Lass-Flörl, C

N1 - © 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

PY - 2014/4

Y1 - 2014/4

N2 - Mycoses summarized in the hyalohyphomycosis group are heterogeneous, defined by the presence of hyaline (non-dematiaceous) hyphae. The number of organisms implicated in hyalohyphomycosis is increasing and the most clinically important species belong to the genera Fusarium, Scedosporium, Acremonium, Scopulariopsis, Purpureocillium and Paecilomyces. Severely immunocompromised patients are particularly vulnerable to infection, and clinical manifestations range from colonization to chronic localized lesions to acute invasive and/or disseminated diseases. Diagnosis usually requires isolation and identification of the infecting pathogen. A poor prognosis is associated with fusariosis and early therapy of localized disease is important to prevent progression to a more aggressive or disseminated infection. Therapy should include voriconazole and surgical debridement where possible or posaconazole as salvage treatment. Voriconazole represents the first-line treatment of infections due to members of the genus Scedosporium. For Acremonium spp., Scopulariopsis spp., Purpureocillium spp. and Paecilomyces spp. the optimal antifungal treatment has not been established. Management usually consists of surgery and antifungal treatment, depending on the clinical presentation.

AB - Mycoses summarized in the hyalohyphomycosis group are heterogeneous, defined by the presence of hyaline (non-dematiaceous) hyphae. The number of organisms implicated in hyalohyphomycosis is increasing and the most clinically important species belong to the genera Fusarium, Scedosporium, Acremonium, Scopulariopsis, Purpureocillium and Paecilomyces. Severely immunocompromised patients are particularly vulnerable to infection, and clinical manifestations range from colonization to chronic localized lesions to acute invasive and/or disseminated diseases. Diagnosis usually requires isolation and identification of the infecting pathogen. A poor prognosis is associated with fusariosis and early therapy of localized disease is important to prevent progression to a more aggressive or disseminated infection. Therapy should include voriconazole and surgical debridement where possible or posaconazole as salvage treatment. Voriconazole represents the first-line treatment of infections due to members of the genus Scedosporium. For Acremonium spp., Scopulariopsis spp., Purpureocillium spp. and Paecilomyces spp. the optimal antifungal treatment has not been established. Management usually consists of surgery and antifungal treatment, depending on the clinical presentation.

KW - Antifungal Agents

KW - Fusarium

KW - Humans

KW - Hyalohyphomycosis

KW - Scedosporium

U2 - 10.1111/1469-0691.12465

DO - 10.1111/1469-0691.12465

M3 - Article

C2 - 24548001

SN - 1198-743X

VL - 20 Suppl 3

SP - 27

EP - 46

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

ER -